Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
| ▸ | IL1RN | P18510 | 2/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8415721 | 1.00 | MMP2 (0.42) | MMP2MMP1MMP14IL1RNERAP2 | |
| SCHEMBL8418352 | 0.81 | ACE (0.46) | MEN1KMT2AMAPTMGAMGAA | |
| SCHEMBL8415706 | 0.81 | ACE (0.46) | MEN1KMT2AMAPTMGAMGAA | |
| SCHEMBL8420365 | 0.79 | MMP9 (0.39) | MMP2MMP1IL1RNERAP2ERAP1 | |
| SCHEMBL8418341 | 0.79 | MMP9 (0.39) | MMP2MMP1IL1RNERAP2ERAP1 | |
| SCHEMBL8354795 | 0.78 | MMP2 (0.52) | MMP2MMP1MMP14IL1RNERAP2 | |
| SCHEMBL8227038 | 0.78 | BMP1 (0.51) | MMP2MMP1MMP14IL1RNERAP2 | |
| SCHEMBL8221838 | 0.78 | BMP1 (0.51) | MMP2MMP1MMP14IL1RNERAP2 | |
| SCHEMBL14446077 | 0.77 | LNPEP (0.49) | MMP2MMP1MMP14IL1RNERAP2 | |
| SCHEMBL14446810 | 0.77 | LNPEP (0.49) | MMP2MMP1MMP14IL1RNERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335726-B2 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | NGLY1, LSS, NRDC | MMP2 2666/4885MMP1 3776/4885MMP14 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.